Clinical Trials

18F-DCFPyL: A Second Generation Low-Molecular Weight PSMA-based PET Radiotracer

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA), [18F]DCFPyL (DCFPyL) PET/CT (or PET/MRI imaging if available) for detection of metastatic prostate cancer.


Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients with Renal Cell Carcinoma

The objective of this study is to evaluate diagnostic utility of PSMA-targeted 18F-DCFPyL PET/CT in patients with renal cell carcinoma.


Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

The objective of this study is to evaluate 18F-DCFPyL to find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.


Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients with Castration-Resistant Prostate Cancer

The objective of this study is tovalidate 18F-DCFPyL for imaging patients with metastatic, castrate-resistant PCa (CRPC), so that it may be used to full advantage in supporting existing and emerging therapies for a spectrum of patients suffering from PCa.


Targeted Imaging of Glutamate Carboxypeptidase II with 18F-DCFPyL-PET

The objective of this study is to use 18F-DCFPyL imaging agent and PET/CT to detect prostate cancer solid malignancies and schwannoma tumors.


Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR)

The objective of this study is to evaluate the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.


Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men with an Elevated PSA Following Radical Prostatectomy

This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.


Study of 18F-DCFPyL PET/CT Imaging in Patients with Prostate Cancer (OSPREY)

This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy.


11C-DPA-713: A Translocator Protein (TSPO) based PET Tracer for the Detection of Tuberculosis

Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States

The objective of this study was to use PET-based neuroimaging with [11C]DPA-713 to quantify regional distribution of translocator protein (TSPO), a putative marker of inflammation, in the brains of patients with schizophrenia and bipolar disorder, type I. The investigators were focused on patients in the early stages of disease to minimize the confounds of age-, chronic illness-, and medication- effects on our results

patents

Issued and Pending*

 

Imaging agents and methods of imaging NAALADase or PSMA, U.S. Patent Number US10340864; M. G. Pomper, J. Zhang, A. Kozikowski, J. Musachio.


Imaging infection with compounds that  bind to thymidine kinase, U.S. Patent Number US11629607; M.G. Pomper, C. Bettegowda, C.Foss, S. Zhou, K. Kinzler, B. Vogelstein.


Cancer imaging with therapy: theranostics U.S. Patent Number US13881777; M. G. Pomper, H. Bhang, P. Fisher.


Theranostic imaging agents and methods of use, Patent Number WO-2012135592-A2; M. G. Pomper, Z. Bhujwalla,  Z. Chen, C. Li, S. Nimmagadda, M. Penet, S. Ray


Pamam dendrimer based CEST imaging agents and uses thereof, Patent Number WO-2017075171-A2; W. Lesniak, S. Nimmagadda, N. Oskolkov, M. Mcmahon, X. Song, M. G. Pomper.


Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (mri), Patent Number WO-2014186737-A1; X. Yang, X. Song, S. Ray, M. G. Pomper, M. T. Mcmahon.


Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen and uses thereof, Patent Number US-2018264143-A1; S. Ray, X. Yang, X. Song, M. T. McMahon, M. G. Pomper.


Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer, Patent Number WO-2017165473-A1; S. Ray, M. G. Pomper.


Glucose conjugates of triptolide, analogs and uses thereof, Patent Number CA-3013619-A1; J. Liu, Q. HE, M. G. Pomper, I. Minn, Biao Yu, Q. Wang.


Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma), Patent Number WO-2018129284-A1; C. Barinka,  M.G. Pomper, Z. Novakova, C. A. Foss.


Imaging and therapy of virus-associated tumors, Patent Number US-2011176998-A1; M. G. Pomper, R. Ambinder, J. O. Liu, C. R. Chong, J. Chen.


Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor, Patent Number WO-2005000250-A2; M. G. Pomper, J. L. Musachio, H. Fan, R. F. Dannals, C. Foss, E. Phillips, J. Gordon, D. Mccarthy, R. Keith, M. Smith, D. Heys, P. Dorf.


TSPO-targeting compounds and uses thereof, Patent Number US-8778304-B2; M. G. Pomper, H. Wang, T. R. Guilarte.


PSMA-based molecular-genetic reporter system, Patent Number US-2017218464-A1; M. G. Pomper, M. Castanares, I. Minn, S. Lupold.


Synthesis and application of novel imaging agents conjugated to DPA 713 analogs for imaging inflammation, Patent Number WO-2013138612-A1; M. G. Pomper, H. Wang, C. Foss.


Bioluminescence imaging-based screening assay and inhibitors of abcg2, Patent Number WO-2010056858-A2; M. G. Pomper, Y. Zhang, J. Laterra.


Ameliorating systemic sclerosis with death receptor agonists, Patent Number CA-3008392-A1; S. Lee, M. G. Pomper, J. Park, Y. OH, M. Scully, M. Horton.


Synthesis and use of targeted radiation enhancing iron oxide-silica-gold nanoshells for imaging and treatment of cancer, Patent Number WO-2015070036-A1; R. Ivkov, L. Woodard, M. G. Pomper.


Tripartite cancer theranostic nucleic acid constructs, Patent Number US-2016106866-A1; P. B. Fisher, S. K. Das, Mitchell E. Menezes, D. Sarkar, M. G. Pomper.


Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections, Patent Number US-2015250906-A1; S. K. Jain, M. G. Pomper, E. A. Weinstein, A. Ordonez, M. Klunik.


Compositions of nucleic acid-containing nanoparticles for in vivo delivery, Patent Number US-2016331845-A1; H. Mao, J. M. Williford, M. Archang, I. Minn, Y. Ren, J. L. Santos, M. G. Pomper.


PEG-Prom mediated surface expression of avidin/streptavidin, Patent Number US-9994865-B2; P. B. Fisher, S. K. Das, M. E. Menezes, D. Sarkar, M. G. Pomper.


Light-Emitting Versions of the Monoclonal Antibody to C3D (MAB 3D29) for Imaging, Patent Number US-2017290930-A1; M. G. Pomper, C. A. Foss, J. M. Thurman, V. M. Holers.


Compositions and methods for sensitizing cells to trail-induced apoptosis, Patent Number US-2018050090-A1; S. Lee, M. G. Pomper, M. Swierczewska, Y. Oh.


Compositions and methods for treating pancreatitis and pain with death receptor agonists, Patent Number WO-2017177148-A1; S. Lee, M. G. Pomper, O. Park, M. Swierczewska, P. J. Pasricha.


Sensitizing cancer to death receptor agonists with kinase inhibitors, Patent Number WO-2017127495-A1; S. Lee, M. G. Pomper, Y. OH, M. Swierczewska.


18F-FNDP for PET imaging of soluble epoxide hydrolase (sEH), Patent Number WO-2017192854-A1; A. Horti, M. G. Pomper, N. J. Alayed.


Reversible pegylation for screeing of therapeutic proteins in vivo, Patent Number WO-2015188110-A1; S. Lee, Y. OH, M. G. Pomper, M. Swierczewska.

Cyclohexyl EDTA monohydride, U.S. Patent Number 5,021,571; RC Mease, SC Srivastava.


Cyclohexyl-triethylenetetra¬amine hexaacetic acid, U.S. Patent Number 5,089,663; RC Mease, SC Srivastava, JF Gestin.


Stable radiometal antibody immunoconjugates, U.S. Patent Number 5,334,729; RC Mease, SC Srivastava, JF Gestin.


Synthesis of 4-substituted trans- 1,2 -diaminocyclohexylpolyaminocarboxylate metal chelating agents for the preparation of stable radiometal antibody immunoconjugates for therapy and SPECT and PET imaging, U.S. Patent Number 5,292,938; RC Mease, LF Mausner, SC Srivastava.


Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal-antibody immunoconjugates for therapy, SPECT and PET imaging, U.S. Patent Number 5,428,156;  RC Mease, LF Mausner, SC Srivastava.


Synthesis of 4-substituted trans-1,2-diaminocyclohexylpolyaminocarboxylate chelating agents for preparation of stable radiometal antibody immunoconjugates for therapy and SPECT and PET imaging, U.S. Patent number 5,635,157;  R.C. Mease, K.L. Kolsky, L.F. Mausner, S.C.Srivastava.


Macrocyclic polyaminocarboxylates for stable radiometal-antibody conjugates for therapy, SPECT, and PET imaging, U.S. Patent Number 5,639,879;  RC Mease, LF Mausner, SC Srivastava.


New rigid bifunctional chelating agents:  Cis-diendo-2,3-diaminobicycloalkane-N,N,N,N,-tetraacetic acid, U.S. Patent Number 5,783,169;  M.P. Sweet, R.C. Mease, S.C. Srivastava.


(Aminostyryl)pyridinium compounds for radiolabeling cell membranes, U.S. Patent Number 5,840,859;  C. Lambert, R.C. Mease J.G. McAfee.


Rigid bifunctional chelating agents, U.S. Patent Number 6,022,522;  M.P. Sweet, R.C. Mease, S.C. Srivastava.

PSMA-binding agents and uses thereof. U.S. Patent Number 8,778,305; M.G. Pomper, R.C. Mease, Y. Chen.


PSMA-targeting compounds and uses thereof. U.S. Patent Number 9,056,841-B2; M.G. Pomper, R.C. Mease, S.R. Banergee, Y. Chen.


Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Biological evaluation, and use as imaging agents. U.S. Patent Number 9,044,468-B2 M.G. Pomper, R.C. Mease, S.R. Banergee, C. Foss.


PSMA-binding agents and uses thereof. U.S. Patent Number 9,226,981-B2; M.G. Pomper, R.C. Mease, Y Chen.


Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof. U.S. Patent Number 9,371,360-B2; M.G. Pomper, S Ray, R.C. Mease, H Shallal.


Prostate specific membrane antigen targeted nanoparticles for therapy of prostate cancer. U.S. Patent Number 9,422,234-B2; SS Chandran, S Ray, M.G. Pomper, SR Denmeade, R.C. Mease.


Labelled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use of imaging agents. U.S. Patent Number 9,694,091-B2; M.G. Pomper, S Ray, R.C. Mease, and CA Foss.


PSMA-targeting compounds and uses thereof. U.S. Patent Number 9,776,977-B2; M.G. Pomper, R.C. Mease, S Ray.

PSMA-binding agents and uses thereof. U.S. Patent Number 9,861,713-B2; M.G. Pomper, RC Mease, Y Chen.


Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof. U.S. Patent Number 9,884,132; M.G. Pomper, S Ray, R.C. Mease, H Shallal.


Preparation of glutamic acid heterodimer prostate-specific membrane antigen PSMA binding agents for therapeutic and imaging use. PCT Int. Appl (2010), WO2010014933 A2 20100204; M.G. Pomper, R.C. Mease, Y. Chen.


Red fluorescent aldehyde dehydrogenase (ALDH) substrate and method for distinguishing ALDH-expressing cells in mixed cell population. PCT Int. Appl. (2014), WO 2014130834 A1 20140828; M.G. Pomper, H.Wang, I. Minn, S.Leach, R.C. Mease.


Preparation of radioactive-4-iodobenzamide derivatives for aldehyde dehydrogenase. PCT Int. Appl. (2014), WO 2014145493 A1 20140918; M.G. Pomper, H. Wang, I. Minn, R.C. Mease.


Prostate Specific membrane antigen targeted photosensitizers for photodynamic therapy. PCT Int. Appl. (2015), WO 2015057692 A1; M.G. Pomper, R.C. Mease, Y. Chen.


Preparation of Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy. PCT. Int. Appl. (2015), WO 2015171792 A1; Ray S, M.G. Pomper, T. J. Meade, R.C. Mease, Y. Chen, X. Yang.


PSMA targeted reversed carbamates and methods of use thereof. PCT. Int. Appl. (2016), WO 2016065145 A2; M.G. Pomper, R.C. Mease, S.Ray, Y. Chen, X. Yang, G. Attardo.


New scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy. PCT. Int. Appl. (2016), WO 2016065142 A2; M.G. Pomper, R.C. Mease, S. Ray, Y. Chen Y, X. Yang.


Derivatives of dibenzothiophene imaging of alpha-7 nicotinic acetylcholine receptors. U.S. Pat. Appl. US 20160235869 A1 20160818; Y. Gao, A. Horti, R. Dannals, R. Wahl, R. Mease, K. Kellar, P. Finley, M. Pomper.


68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents. PCT Int. Appl. (2016), WO 2016149188 A1 20160922; M.G. Pomper, R.C. Mease, R. Sangeeta.


Nuclear imaging and radiotherapeutic agents targeting carbonic anhydrase IX and uses thereof. PCT Int. Appl (2016) WO 2016196628 A1 20161208, Yang X, Rowe S, Ray S, R.C. Mease, Gorin M, Allaf M, M.G. Pomper.


Preparation of prostate-specific membrane antigen based carbamate and beta-amino acid urea-based scaffolds for imaging and radiotherapy and PSMA-targeted photosensitizers for photodynamic therapy. PCT Int. Appl. (2016), WO 2016065142 A2 2-160428; M.G. Pomper, R.C. Mease, S. Ray, Y. Chen, X. Yang.


Preparation of prostate-specific membrane antigen targeted reversed carbamate based scaffolds and for imaging and radiotherapy and PSMA-targeted photosensitizers for photodynamic therapy. PCT Int. Appl. (2016), WO 2016065145 A2 20160428; M.G. Pomper, R.C. Mease, S.Ray, Y. Chen, X. Yang, G. Attardo.


Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (CX3CR1). PCT Int. Appl. (2016), WO 2016200939 A1 20161215; M.G. Pomper, R.C. Mease, X. Yang, C. Foss.


Prostate-Specific membrane antigen-targeted photosensitizers for photodynamic therapy. U.S. Pat. Appl. Publ. (2016) US 2016/0235865 A1; M.G. Pomper, R.C. Mease, Y. Chen.


Preparation of triazole conjugated ureas, thioureas, carbamates, and “reversed” carbamates prostate-specific membrane antigen-targeted imaging agents and their uses. PCT Int. Appl. (2017), WO 2017027870 A1 20170216; M.G. Pomper, Y. Chen, X. Yang, R.C. Mease, S Ray.


Preparation of PSMA targeted radiohalogenated urea peptidomimetrics for cancer therapy. PCT Int. Appl. (2017), WO 2017070482 A2 20170427; M.G. Pomper, R.C. Mease, Y. Chen, S. Ray, M. Zalutsky, G. Vaidyanathan.


Prostate-specific membrane antigen (PSMA) targeted fluorescent agents for image guided surgery. U.S. Pat. Appl. Publ. (2017) US 20170283384 A1 20171005; M.G. Pomper, R.C. Mease, Y. Chen, S. Ray, J. Sorger.


Nuclear imaging and radiotherapeutic agents targeting carbonic anhydrase IX and uses thereof. PCT Int. Appl (2017) WO 2017197251 A1 20171116; X. Yang, I. Minn, S. Rowe, S. Ray, R.C. Mease, M. Gorin, M. Allaf, M.G. Pomper.


An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL. PCT Int. Appl. (2017), WO 2017214470 A1 20171214; H.T. Ravert, D. P. Holt, Y. Chen, R.C. Mease, H. Fan, M.G. Pomper, R. F. Dannals.


Decoy nanoparticles to disrupt cancer cell-stromal cell networks, Patent Number  US20180200194;  Z. M. Bhujwalla, J. Jin, S. Nimmagadda, B. Krishnamachary.


Phosphoramidate Derivatives of Fau, Patent Number US12092999; A. F. Shields,   J. Zemlicka, S. Nimmagadda


*For selected inventions Non-U.S. Patent rights have been pursued. For more information contact Johns Hopkins Technology Ventures

image159